

## NEWS RELEASE

Kuala Lumpur/Singapore, 29 May 2025

### IHH Healthcare delivers resilient operational performance in Q1 2025

- IHH Healthcare maintains its healthcare leadership with revenue up 6% to RM6.3 billion.
- On a constant currency basis, revenue and EBITDA grew 17% and 8% respectively.
- With the ACE Framework as the foundation for our five strategic growth priorities, we've launched a multi-year transformation plan with seven focus areas designed to both accelerate our growth and future-proof our business.

*"We reported resilient operational performance for Q1 2025, driven by an improvement in inpatient volumes and higher revenue intensity across some markets. The Group remains on track to achieve its goal of expanding capacity by 4,000 beds, with 1,000 beds already added last year.*

*At the forefront of clinical excellence, the Group is leading the way in value-based care for our patients. These achievements reflect our continued healthcare leadership. A multi-year transformation journey is also underway to accelerate our growth, ensuring we are well-positioned to deliver long-term value to patients and shareholders.*

**Dr Prem Kumar Nair**  
Group Chief Executive Officer, IHH Healthcare

### GROUP RESULTS – FINANCIAL HIGHLIGHTS<sup>1</sup>

#### Q1 2025 key metrics (Y-o-Y) change

Revenue	EBITDA	PATMI (ex EI)	PATMI
<b>RM6.3b</b>	<b>RM1.3b</b>	<b>RM425m</b>	<b>RM514m</b>
+6%	-2%	+5%	-33%

### GROUP OPERATIONAL SUMMARY (FOR QUARTER ENDED 31 MARCH 2025)



**Occupancy**  
(for Q1 2025)

**69% (-1%)**



**Inpatient Admissions**  
(for Q1 2025)

**226,951 (+4%)**



**Lab Tests**  
(for Q1 2025)

**26 million (+5%)**

<sup>1</sup> The Group's headline performance includes the application of the MFRS 129 accounting standard (Financial Reporting in Hyperinflationary Economies) relating to its entities in Türkiye.

### **Q1 2025: Healthy revenue growth, underpinned by strong operations**


- Revenue increased 6% year-on-year while EBITDA declined slightly by 2% year-on-year. The growth in revenue was mainly attributable to increased contributions from Malaysia and Türkiye & Europe despite the full Ramadan holiday period impacting many markets in Q1 2025, which was spread across Q1 and Q2 in 2024.
- On a constant currency basis, revenue grew 17% year-on-year and EBITDA increased 8% year-on-year, reflecting strong operational resilience.
- Q1 2025 finance costs rose mainly due to higher interest costs from acquisitions, such as Island Hospital and Agilus.
- EBITDA contributions increased across some segments, offset by decreased EBITDA contributions from Singapore due to bed closures from the ongoing renovation works at Mount Elizabeth Hospital and pre-operational start-up cost relating to new hospitals in Türkiye & Europe.
- PATMI decreased 33% against last year mainly due to a lower net monetary gain from the application of MFRS 129, and the recognition of deferred tax credit last year arising from the revaluation of certain assets in Türkiye as allowed by the Türkiye government. Excluding exceptional items, PATMI (ex EI) increased 5% on core operational growth.
- We've launched a multi-year transformation plan with seven focus areas - clinical excellence, patient experience, new care models, operational excellence, payor and regulator engagement, employee and doctor value proposition, and the advancement of technology, data, and artificial intelligence. This transformation plan will accelerate the growth of our strategic priorities and future-proof our business.
- While facing continued payor pressure in many of our markets, we are actively collaborating with regulators and payors to address the challenge of increasing medical inflation costs.
- Our highly diversified healthcare portfolio, spanning multiple geographies, provides significant business resilience. This geographical spread allows us to buffer the impact of pressures in some countries with the strong performance of others, giving us a key strategic advantage.

### **Post Q1 2025:**

- Shareholders and their proxies voted to approve all 10 ordinary resolutions tabled at the 15th Annual General Meeting on 28 May 2025.
- IHH Healthcare secured its first S\$300 million sustainability-linked loan, strengthening its ongoing commitment to integrating and upholding sustainable practices across its operations.

## GROUP OUTLOOK

### IHH's 2025 strategic growth priorities :



- Amid rising healthcare demands domestically and across its key markets, the Group remains confident in its growth path.
- We have initiated a multi-year transformation plan to future-proof our business through continuous improvements and accelerate our growth priorities.
- The Group's transformation will be driven by seven focus areas - clinical excellence, patient experience, new care models, operational excellence, payor and regulator engagement, employee and doctor value proposition, and the advancement of technology, data, and artificial intelligence.
- The Group expects continued revenue growth driven by healthcare megatrends and will focus on driving profitability and sustaining healthy ROE while maintaining prudent capital management and mitigating inflationary and interest rate pressures.

+++

## ABOUT IHH HEALTHCARE BERHAD (“IHH”)

A world-leading integrated healthcare provider, IHH believes that making a difference starts with our aspiration to Care. For Good.

Our team of more than 70,000 people commit to deliver greater good to our patients, people, the public and planet, as we live our purpose each day to touch lives and transform care.

Through our portfolio of trusted brands – Acibadem, Mount Elizabeth, Prince Court, Island Hospital, Gleneagles, Fortis, Pantai and Parkway – we offer our patients comprehensive and personalised care ranging from primary to quaternary, and even ancillary services such as laboratory, diagnostics, imaging and rehabilitation.

With a clear focus on clinical excellence and innovation, we continue to raise the bar in healthcare in our key markets of Malaysia, Singapore, Türkiye, India, Greater China (including Hong Kong) and beyond.

In partnership with our stakeholders, we will co-create a sustainable future for all as we work towards our vision to become the world’s most trusted healthcare services network.

More information can be found at [www.ihhhealthcare.com](http://www.ihhhealthcare.com).

+++

*For more information or to speak to an IHH spokesperson, please contact:*

Kelvin Chong  
Investor Relations, IHH Healthcare  
t. +65 9489 5357  
e. [kelvin.chong@ihhhealthcare.com](mailto:kelvin.chong@ihhhealthcare.com)

Joshua Kuek  
Investor Relations, IHH Healthcare  
t. +65 9675 3585  
e. [joshua.kuek@ihhhealthcare.com](mailto:joshua.kuek@ihhhealthcare.com)